Immune responses against SIV envelope glycoprotein, using recombinant SV40 as a vaccine delivery vector (Q77148428)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12297408%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

title

Immune responses against SIV envelope glycoprotein, using recombinant SV40 as a vaccine delivery vector (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12297408%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

author name string

Hayley J McKee

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12297408%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

David S Strayer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12297408%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

language of work or name

English

0 references

publication date

1 October 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12297408%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

number of pages

13

1 reference

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12297408%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12297408%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

issue

29-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12297408%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

page(s)

3613-3625

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12297408%20AND%20SRC:MED&resulttype=core&format=json

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

3 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Multi-drug resistant HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

A pilot study of low-dose zidovudine in human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

HIV positive patients first presenting with an AIDS defining illness: characteristics and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

1 reference

7 January 2021

Why do we not have an HIV vaccine and how can we make one? .

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Macaque models for AIDS vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Progress in the development of an HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

HIV vaccines: where we are and where we are going

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

New viral vectors for HIV vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

A replication-deficient rSV40 mediates liver-directed gene transfer and a long-term amelioration of jaundice in gunn rats

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

HIV-1 Nef blocks transport of MHC class I molecules to the cell surface via a PI 3-kinase-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Evolution and plasticity of CTL responses against HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

T cell responses and viral escape

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication in primary CD4(+) T lymphocytes, monocytes, and dendritic cells by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Immune modulation by IL-10 gene transfer via viral vector and plasmid DNA: implication for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Incorporation of cells into an ELISA system enhances antigen-driven lymphokine detection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Optimization of cellular ELISA for assay of surface antigens on human synoviocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Natural cell-mediated immunity in the rabbit.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Simian virus 40 infection via MHC class I molecules and caveolae

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

MHC class I molecules are enriched in caveolae but do not enter with simian virus 40.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

Subcellular distribution of simian virus 40 T antigen species in various cell lines: the 56K protein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900243-8

7 January 2021

10.1016/S0264-410X(02)00243-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12297408%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference